The IP6K3 antibody is a crucial tool for studying inositol hexakisphosphate kinase 3 (IP6K3), a member of the IP6K family that catalyzes the synthesis of 5-diphosphoinositol pentakisphosphate (5-IP7) from inositol hexakisphosphate (IP6). IP6K3 plays a role in diverse cellular processes, including apoptosis, autophagy, metabolic regulation, and immune responses. It is highly expressed in tissues such as the brain, liver, and kidneys, and its dysregulation has been linked to metabolic disorders (e.g., obesity, diabetes), neurodegenerative diseases, and cancer. Unlike its isoforms IP6K1 and IP6K2. IP6K3 exhibits distinct substrate preferences and subcellular localization, suggesting unique functional roles.
IP6K3 antibodies are typically generated using recombinant proteins or peptide epitopes from conserved regions of the human IP6K3 protein, with common hosts being rabbits or mice. These antibodies enable the detection and quantification of IP6K3 expression in various experimental applications, such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and immunoprecipitation (IP). Validated antibodies show specificity through knockout cell line controls, ensuring minimal cross-reactivity with other IP6K isoforms. Researchers utilize IP6K3 antibodies to explore its involvement in cellular signaling pathways, metabolic homeostasis, and disease mechanisms. Recent studies highlight its potential as a therapeutic target, particularly in metabolic syndrome and neurological conditions. Proper antibody validation remains essential to ensure reliable data in both basic and translational research contexts.